Initial Management of Hemoptysis

Assessment and Management

The American College of Chest Physicians recommends immediate assessment of severity and airway protection as the first priority in cases of massive hemoptysis, with endotracheal intubation and optimal oxygenation as initial management steps 1, 2
Massive hemoptysis is defined as hemoptysis placing the patient at high risk for asphyxiation or exsanguination, traditionally ≥200 mL in 24 hours, with the rate of bleeding more closely associated with morbidity and mortality than the total quantity 1, 3
The American College of Radiology suggests that two or more opacified lung quadrants on chest radiograph correlate with increased mortality risk 3
Bronchial artery embolization (BAE) has become the first-line therapy for massive hemoptysis with immediate success rates of 73-99%, and is recommended for clinically unstable patients without delay 2, 4
The American College of Chest Physicians recommends considering selective right or left mainstem intubation to protect the non-bleeding lung, and using bronchoscopic management techniques such as tamponade, iced saline instillation, and bronchial blockade balloons for airway clearance 2, 5
For clinically stable patients with significant hemoptysis, CT chest with IV contrast is the preferred initial diagnostic test to identify cause and location of bleeding, and bronchoscopy provides valuable information on the anatomic site and side of bleeding 6, 5
Delaying BAE in clinically unstable patients with massive hemoptysis significantly increases mortality, and performing bronchoscopy before BAE in unstable patients is not recommended 6
Recurrence of bleeding occurs in 10-55% of cases after BAE, requiring close follow-up, and continuing NSAIDs or anticoagulants during active hemoptysis can worsen bleeding 6, 7

Management of Hemoptysis with Diagnostic Imaging and Interventional Procedures

Diagnostic Evaluation and Interventional Management

For clinically stable patients, chest radiograph is a reasonable initial imaging choice, especially when confirming benign causes like acute bronchitis or pneumonia, as recommended by the American College of Radiology 8, 9
CTA has become the standard of care for arterial planning if bronchial artery embolization (BAE) is being considered, with the American College of Radiology supporting its use 8, 9
Higher recurrent hemoptysis rates are associated with specific conditions, including chronic pulmonary aspergillomas (55% recurrence rate), malignancy, and sarcoidosis, according to the American College of Radiology 8, 10
For patients with aspergillomas causing hemoptysis, definitive surgical treatment following initial BAE for acute massive hemoptysis is recommended due to high recurrence rates, as suggested by the American College of Radiology 8, 10
BAE for malignancy is typically either palliative or performed as a temporizing measure prior to definitive surgery, as stated by the American College of Radiology 8, 10
Recurrent hemoptysis within 3 months of initial BAE is often due to incomplete or missed embolization of bleeding arteries, while treatment failure after 3 months is most likely due to vascular collateralization or recannulation, according to the American College of Radiology 8, 10
Recent studies have consistently shown no increased risk of morbidity or mortality for repeat BAE interventions following recurrent hemoptysis, as reported by the American College of Radiology 8, 10

Management of Massive Hemoptysis

Immediate Airway Management and Stabilization

Intubate immediately with a single-lumen cuffed endotracheal tube to allow bronchoscopic suctioning and clot removal, as recommended by the American Thoracic Society, with a success rate of 73-99% 11
Administer high-flow oxygen and establish large-bore IV access (ideally 8-Fr central line) to ensure adequate oxygenation and circulation, according to the American Society of Anesthesiologists 12

Post-Intervention Management

Admit all patients to intensive care for monitoring of coagulation parameters, hemoglobin, blood gases, and ongoing bleeding, as suggested by the Society of Critical Care Medicine 12
Actively warm the patient and all transfused fluids, and start venous thromboprophylaxis as soon as bleeding is controlled, as recommended by the American College of Chest Physicians 12

Management of Massive Hemoptysis with Respiratory Distress

Initial Assessment and Intervention

The American Journal of Respiratory and Critical Care Medicine recommends avoiding BiPAP in massive hemoptysis, as positive pressure can worsen bleeding, in patients with respiratory distress 13
The American Journal of Respiratory and Critical Care Medicine suggests stopping all airway clearance therapies immediately in massive hemoptysis to allow clot formation, which is crucial for patients with significant bleeding 13

Critical Pitfalls to Avoid

The American Journal of Respiratory and Critical Care Medicine advises against delaying airway protection in favor of diagnostic procedures when the patient has respiratory distress, emphasizing the importance of prompt intervention 13

Management of Hemoptysis with Bronchoscopic and Radiologic Interventions

Bronchoscopic Management

The American Thoracic Society recommends bronchoscopic interventions, including argon plasma coagulation, Nd:YAG laser, electrocautery, tamponade with iced saline, and bronchial blockade balloons, for visible central airway lesions causing hemoptysis, achieving 80-90% success rates 14
External beam radiation therapy (EBRT) is recommended for distal or parenchymal lesions not amenable to bronchoscopic intervention, achieving 81-86% hemoptysis relief rates 14
Combined high-dose rate brachytherapy with EBRT provides better symptom relief than EBRT alone, though fatal hemoptysis rates range from 7-22% 14

Surgical Management

Surgery may be considered for surgically resectable tumors in stable patients with 50-70% survival rates, according to the American College of Chest Physicians 14
In a 10-year experience, surgical management of massive hemoptysis carried 16% mortality, associated with blood aspiration into contralateral lung and pneumonectomy 14

Management of Hemoptysis with Bronchial Artery Embolization

Initial Assessment and Management

The American Thoracic Society recommends that for clinically unstable patients with massive hemoptysis, proceeding directly to bronchial artery embolization (BAE) without bronchoscopy achieves immediate hemostasis in 73-99% of cases 15
The use of a single-lumen cuffed endotracheal tube allows for effective bronchoscopic suctioning and clot removal, with a larger diameter enabling rapid removal of obstructing clots 15

Bronchoscopic Management Techniques

The American College of Chest Physicians recommends the use of tamponade, iced saline instillation, bronchial blockade balloons, topical hemostatic tamponade, and thermal ablation for visible central airway lesions 15, 16
Topical hemostatic tamponade with oxidized regenerated cellulose mesh arrests hemoptysis in 98% of cases 15
Thermal ablation using argon plasma coagulation, Nd:YAG laser, or electrocautery can be used for visible lesions 15, 16

Management of Non-Massive Hemoptysis

The American College of Chest Physicians recommends performing bronchoscopy to identify the source of bleeding in patients with mild-to-moderate or scant hemoptysis 16
For visible central airway lesions, endobronchial management options such as argon plasma coagulation, Nd:YAG laser, and electrocautery can be used 16

Specific Management Considerations

For unresectable lung cancer with non-massive hemoptysis, external beam radiation therapy (EBRT) provides palliation in approximately 60% of patients, with hemoptysis being the best-palliated symptom (81-86% relief) 15, 16
Combined high-dose rate brachytherapy with EBRT provides better symptom relief than EBRT alone 16

Surgical Management

Surgery is reserved as a final therapeutic option and is indicated when BAE alone is unsuccessful, or in cases of surgically resectable tumors in stable patients 17
Surgery for massive hemoptysis carries 16% mortality, associated with blood aspiration into the contralateral lung and pneumonectomy 16

Hemoptysis Management

Diagnostic Approach

The American College of Radiology recommends CT chest with IV contrast as the primary imaging modality to determine the etiology of nonmassive hemoptysis, superior to bronchoscopy and arteriography for identifying the cause 18, 19
Chest radiograph is a reasonable initial choice when confirming benign causes like acute bronchitis or pneumonia, but it has limited sensitivity and suggests the etiology in only 26% of cases 18, 19, 20

Treatment Approach

The American College of Radiology suggests that bronchial artery embolization (BAE) is the first-line therapy for massive hemoptysis with immediate success rates of 73-99%, as over 90% of massive hemoptysis originates from bronchial arteries 21
BAE should be performed without delay in clinically unstable patients, and conventional arteriography is performed with therapeutic intent, not as a diagnostic modality 21
For nonmassive hemoptysis, BAE is increasingly utilized when conservative medical therapy fails or for palliation, with immediate bleeding cessation in 93% of patients 18, 19, 20

Management of Recurrent Hemoptysis

For recurrent hemoptysis following initial treatment, repeat BAE is the primary therapeutic option, with recent studies showing no increased risk of morbidity or mortality for repeat interventions 18
CT angiography (CTA) or CT with IV contrast should be performed before repeat BAE for arterial mapping 18, 19

Common Etiologies

Bronchiectasis is the most common cause of hemoptysis in many series 18, 19
Lung cancer is also a common cause of hemoptysis, and BAE for malignancy is typically palliative or a temporizing measure prior to definitive surgery 19
Active tuberculosis is another common cause of hemoptysis 18, 19

Initial Management of Hemoptysis

Immediate Assessment and Stabilization

Establish large-bore IV access (ideally 8-Fr central line) for volume resuscitation and potential transfusion, as recommended by the American Society of Anesthesiologists, to ensure adequate blood flow and oxygenation 22
Obtain baseline labs, including complete blood count, PT/aPTT, fibrinogen (Clauss method, not derived), and type and cross-match, to assess the patient's coagulation status and guide further management 22
Actively warm the patient and all transfused fluids to prevent hypothermia-induced coagulopathy, which can worsen bleeding, as suggested by the American Society of Anesthesiologists 22

Medical Management for Non-Massive Hemoptysis

Avoid hyperventilation and excessive positive end-expiratory pressure in hypovolemic patients, as this can worsen hemodynamics, according to the Society of Critical Care Medicine 23
Do not rely on single hematocrit measurements as an isolated marker for bleeding severity, as recommended by the Society of Critical Care Medicine, and instead use a combination of clinical and laboratory parameters to assess the patient's condition 23
Do not use derived fibrinogen levels, as they are misleading, and instead use Clauss fibrinogen to assess coagulation status, as suggested by the American Society of Anesthesiologists 22

Management of Massive Hemoptysis

Initial Airway Management

In patients with massive hemoptysis, the American Thoracic Society recommends avoiding BiPAP entirely, as positive pressure ventilation worsens bleeding 24
For patients with massive hemoptysis, stopping aerosolized hypertonic saline is recommended, as it can exacerbate bleeding 24
In massive hemoptysis, stopping all airway clearance therapies immediately is recommended to allow clot formation 24
Continue airway clearance therapies in scant hemoptysis, as stopping is inappropriate 24
For mild-to-moderate hemoptysis, active cycle of breathing and autogenic drainage are least concerning 24
Continue aerosol therapies (except hypertonic saline) in scant hemoptysis 24
In massive hemoptysis, stop aerosolized hypertonic saline but general aerosol therapy recommendations vary 24
Lung resection should be performed only as a final therapeutic option in massive hemoptysis after other measures (e.g., BAE) have failed 24

Management of Hemoptysis

Initial Severity Assessment

Scant hemoptysis (<5 mL/24h) may not require hospital admission, according to the American Thoracic Society, with a recommendation based on studies 25, 26
Massive hemoptysis (>240 mL/24h or any amount causing respiratory compromise) demands immediate intervention with mortality risk up to 59-100% if untreated, as stated by the American College of Chest Physicians 27, 28

Management Pathway for Mild-to-Moderate Hemoptysis

Administer antibiotics for any hemoptysis ≥5 mL, as bleeding may represent pulmonary exacerbation or superimposed bacterial infection, recommended by the American Thoracic Society 25, 26
Stop all NSAIDs immediately due to their effect on platelet function that can worsen bleeding, advised by the American Thoracic Society 25, 26
Admit to hospital for any hemoptysis ≥5 mL for monitoring and treatment, as suggested by the American Thoracic Society 25, 26

Bronchoscopic Interventions

Tamponade by wedging the bronchoscope tip into the bleeding bronchus, instillation of iced saline solution to constrict blood vessels, and bronchial blockade balloons may be used to control bleeding, as described by the American College of Chest Physicians 27, 28
Topical hemostatic tamponade with oxidized regenerated cellulose mesh (98% success rate) can be used to control bleeding, according to the American College of Chest Physicians 27

Management of Hemoptysis

Diagnostic Approach and Treatment

The American College of Radiology recommends CT chest with IV contrast for determining etiology, with 77% diagnostic accuracy, and CTA provides better vessel opacification, detects aberrant bronchial arteries in 36% of cases, and identifies pulmonary artery pseudoaneurysms missed on conventional arteriography 29
The American Journal of Respiratory and Critical Care Medicine suggests administering antibiotics for any hemoptysis ≥5 mL, as bleeding may represent pulmonary exacerbation or superimposed bacterial infection, and stopping all NSAIDs immediately due to their effect on platelet function that worsens bleeding 30
The American College of Radiology states that over 90% of massive hemoptysis originates from bronchial arteries, and for the remaining ~10% with pulmonary arterial bleeding, pulmonary artery embolization achieves 88-90% success rates 29
The American Journal of Respiratory and Critical Care Medicine recommends not delaying BAE for CT imaging or bronchoscopy in unstable patients, as this significantly increases mortality 30

Management of Recurrent Hemoptysis

The American College of Radiology reports that recurrence occurs in 10-55% of cases after initial BAE, with higher rates in chronic pulmonary aspergillomas (55%), malignancy, and sarcoidosis 29

Hemoptysis Definition, Classification, and Evidence‑Based Management

Definition & Epidemiology

Hemoptysis is the expectoration of blood from the lower respiratory tract, most commonly originating from bronchial arteries in >90 % of cases (American College of Radiology) 31.

Volume‑Based Classification

Scant hemoptysis: < 5 mL in 24 h (American College of Radiology) 32.
Mild‑to‑moderate hemoptysis: 5–240 mL in 24 h (American College of Radiology) 32.
Massive hemoptysis: > 240–300 mL in 24 h or any amount causing respiratory compromise or risk of exsanguination (American College of Radiology) 32.

Clinical Risk Stratification

The rate of bleeding correlates more closely with morbidity and mortality than the absolute volume expectorated (American College of Radiology) 31.
Massive hemoptysis is best defined by the risk of asphyxiation or exsanguination, irrespective of exact volume (American College of Radiology) 31.

Hemodynamic Stability Assessment

Clinically unstable patients require immediate airway protection and resuscitation (American College of Radiology) 31.
Clinically stable patients can undergo comprehensive diagnostic evaluation (American College of Radiology) 31.

Common Etiologies (by Setting)

Outpatient/primary‑care setting: acute respiratory tract infections are the most frequent cause; chronic obstructive pulmonary disease, malignancy, and bronchiectasis are also common (American College of Radiology) 31.
Tertiary referral centers (North America/Europe): bronchiectasis is the leading cause, followed by respiratory infections and lung carcinomas (American College of Radiology) 31.
Developing countries: tuberculosis and its sequelae predominate (American College of Radiology) 31.
Additional notable causes: sarcoidosis, autoimmune capillaritis, coagulopathies, pulmonary arteriovenous malformations, pulmonary pseudoaneurysms, pulmonary embolism (uncommon), and cryptogenic hemoptysis (~20 % of cases despite extensive work‑up) (American College of Radiology) 31.

Diagnostic Approach (Cited Points)

In clinically unstable patients, bronchoscopy is performed primarily for airway clearance and tamponade rather than for diagnosis (American College of Radiology) 31.
A chest radiograph is used to assess the number of opacified lung quadrants and verify endotracheal tube placement (American College of Radiology) 31.

Patient Guidance (Cystic Fibrosis & General)

Patients with any hemoptysis ≥5 mL should contact their healthcare provider promptly (American College of Radiology) 32.
Patients with scant hemoptysis (<5 mL) should seek medical advice if it is the first episode or if it persists (American College of Radiology) 32.
Patients experiencing massive hemoptysis must obtain immediate medical attention (American College of Radiology) 32.

Evidence‑Based Recommendations for Hemoptysis Severity Classification and Management

Severity Classification

Hemoptysis should be stratified by volume: scant < 5 mL/24 h, mild‑to‑moderate 5–240 mL/24 h, and massive > 240 mL/24 h or any amount causing respiratory compromise; this classification guides subsequent therapeutic decisions. 33

Management of Scant Hemoptysis ( < 5 mL/24 h )

Patients experiencing a first or persistent episode of scant hemoptysis should be instructed to contact a healthcare provider, but routine hospital admission is not required in the absence of ongoing bleeding. 33
Routine antibiotics are not indicated for scant hemoptysis unless there are clinical features suggestive of a pulmonary infection or exacerbation. 33
Non‑steroidal anti‑inflammatory drugs (NSAIDs) should be discontinued in patients with scant hemoptysis, as they may impair platelet function and exacerbate bleeding. 33

Management of Mild‑to‑Moderate Hemoptysis ( 5–240 mL/24 h )

All patients with ≥ 5 mL of hemoptysis should promptly contact a healthcare provider and be admitted for inpatient monitoring and treatment. 33
Empiric antibiotic therapy should be initiated immediately, given the high likelihood that bleeding reflects a pulmonary infection or superimposed bacterial process. 33
NSAIDs must be stopped promptly because of their potential to worsen hemorrhage by inhibiting platelet aggregation. 33
Anticoagulant agents should be withheld during active bleeding episodes to reduce the risk of ongoing hemorrhage. 33

Management of Massive Hemoptysis ( > 240 mL/24 h or Respiratory Compromise )

Unstable patients with massive hemoptysis require immediate ICU admission and should proceed directly to bronchial artery embolization (BAE) without preceding bronchoscopy; this approach achieves immediate hemostasis in 73 %–99 % of cases. 33
BAE is the first‑line definitive therapy for massive hemoptysis, offering an immediate success rate of 73 %–99 %. 33
In hemodynamically unstable patients, bronchoscopy prior to BAE is not recommended, as delays increase mortality risk. 33

Management of Hemoptysis in Oncology Patients (Cited Evidence)

Airway Management in Massive Hemoptysis

For patients with massive hemoptysis, immediate endotracheal intubation with a single‑lumen tube is recommended to permit therapeutic bronchoscopy and clot removal; double‑lumen tubes are discouraged because they limit bronchoscope access. 34

Immediate Definitive Intervention

In hemodynamically unstable patients, bronchial artery embolization (BAE) should be performed without prior bronchoscopy, as delays increase mortality. BAE achieves immediate hemostasis in 73 %–99 % of cases. 35

Endobronchial Therapies for Visible Lesions

Argon plasma coagulation provides complete control of bleeding lesions with 100 % success at 3‑month follow‑up. 34
Nd:YAG laser therapy yields a therapeutic response in approximately 60 % of treated lesions. 34
Electrocautery produces outcomes comparable to Nd:YAG laser for endobronchial tumor bleeding. 34

External Beam Radiotherapy (EBRT) for Non‑Resectable Tumors

EBRT is indicated for unresectable thoracic malignancies causing hemoptysis, achieving symptomatic relief in 81 %–86 % of patients. 35
Comparative dose regimens show no difference in overall survival or palliation between:
- 30 Gy in 10 fractions vs. 40 Gy in 20 fractions. [34][35]
- 17 Gy in 2 fractions vs. 30 Gy in 10 fractions. 34

Combined Endobronchial Brachytherapy and EBRT

Adding endobronchial brachytherapy to EBRT improves symptom relief compared with EBRT alone, but carries a fatal hemoptysis rate of 7 %–22 %. 35

Procedural Pitfalls to Avoid

Do not perform bronchoscopy before BAE in unstable patients, as this postponement raises mortality risk. 34
Avoid using double‑lumen endotracheal tubes because they are harder to place and limit therapeutic bronchoscope passage. 34
Refrain from administering vasoactive agents (e.g., epinephrine) for massive bleeding, as they are unlikely to be beneficial. 34

Post‑Embolization Outcomes

Recurrence of hemoptysis after BAE occurs in 10 %–55 % of cases, with higher rates in malignant disease. 35

Guideline for Assessment and Management of Hemoptysis ≥ 5 mL

Severity Classification and Prognostic Indicators

Hemoptysis is classified as massive when the volume exceeds 240 mL per 24 h or when any amount causes respiratory compromise; the bleeding rate predicts mortality more accurately than total volume. 36

Initial Diagnostic Imaging

An urgent contrast‑enhanced CT of the chest (within 24 h) is the preferred first‑line test, providing ≈ 77 % diagnostic accuracy for identifying the bleeding source, markedly superior to a chest radiograph (≈ 26 % yield). 36
A chest radiograph alone should not be relied upon for diagnosis because it detects the underlying etiology in only about 26 % of cases and a normal film does not exclude serious pathology. 36

Therapeutic Interventions for Massive Hemoptysis

In hemodynamically unstable patients with massive hemoptysis, bronchial artery embolisation (BAE) should be performed without delay, achieving immediate haemostasis in 73–99 % of cases; bronchoscopy prior to BE in unstable patients increases mortality and should be avoided. 36

Antimicrobial Management

The British Thoracic Society recommends a 14‑day antibiotic course for bronchiectasis‑related infections, using agents active against Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. 37
Empiric therapy for an older adult with productive cough and new hemoptysis may include amoxicillin‑clavulanate (standard dose) for 14 days to cover β‑lactamase‑producing organisms, or ciprofloxacin if Pseudomonas is a concern. 38

Medication Safety

All NSAIDs and anticoagulants should be discontinued immediately in patients with hemoptysis, as they impair platelet function and exacerbate bleeding. 37

Differential Diagnosis Priorities

Malignancy is a leading cause of hemoptysis in tertiary care settings, especially in patients around 70 years old, and should be actively investigated. 36
Bronchiectasis is the most frequent cause in many series; high‑resolution CT reliably identifies bronchiectatic changes. [36][38]
Necrotising pneumonia or lung abscess (often due to Staphylococcus aureus, Klebsiella spp., or anaerobes) can precipitate hemoptysis during treatment. 38
Pulmonary embolism is an uncommon etiology but must be considered when risk factors are present. 36

Follow‑Up and Monitoring

Patients should be admitted to a monitored bed with daily reassessment for recurrent bleeding, response to antibiotics, and emergence of new symptoms. [38][39]
Recurrence of hemoptysis occurs in 10–55 % of cases, with higher rates in malignancy, aspergilloma, and bronchiectasis, underscoring the need for close outpatient follow‑up. 39

Cited Evidence on Etiology and Management of Hemoptysis

Outpatient/Primary‑Care Etiology

Tertiary‑Referral Center Etiology (North America/Europe)

Developing‑Country Etiology

Cryptogenic Hemoptysis

Diagnostic Considerations

Hemoptysis Management Guidelines (American College of Radiology)

Definition & Classification

Hemoptysis is defined as expectoration of blood from the lower respiratory tract; severity is stratified by both volume and clinical risk rather than volume alone, with rapid bleeding rate more strongly predicting mortality than absolute volume 41, 42.
Massive hemoptysis is defined as >240–300 mL/24 h or any amount causing respiratory compromise, hypotension, or risk of asphyxiation 41, 42.
Clinically unstable patients (respiratory distress, hemodynamic compromise, or ongoing massive bleeding) require immediate airway protection and therapeutic intervention without diagnostic delay 41.
Clinically stable patients may undergo comprehensive diagnostic evaluation before definitive therapy 41.

Etiology (Population‑Specific)

In outpatient primary‑care settings in high‑income regions, acute respiratory tract infections account for ≈63 % of hemoptysis cases with a normal chest radiograph 41, 42.
Chronic obstructive pulmonary disease (COPD) is a common outpatient cause 41, 42.
Malignancy was identified in 22 of 270 patients presenting with hemoptysis and a normal chest radiograph 41.
Bronchiectasis is a frequent outpatient etiology 41, 42.
In tertiary referral centers in high‑income regions, bronchiectasis is the leading cause, followed by respiratory infections and lung carcinomas 41, 42.
In low‑ and middle‑income regions, tuberculosis and its sequelae predominate 41, 42.
Sarcoidosis is associated with higher recurrence rates after bronchial artery embolization 41, 42.
Autoimmune diseases (e.g., capillaritis) and coagulopathies are recognized etiologies 41, 42.
Vascular abnormalities—including pulmonary arteriovenous malformations, pseudoaneurysms, and aneurysms—contribute to hemoptysis 41, 42.
Pulmonary embolism is an uncommon cause, reported as a primary etiology in a single study 41, 42.
Chronic pulmonary aspergillomas have a 55 % recurrence rate after bronchial artery embolization alone 42.
Approximately 20 % of hemoptysis cases remain cryptogenic despite exhaustive imaging and bronchoscopy 41, 42.

Clinical Assessment (Initial 5 Minutes)

Quantification of blood volume (patient estimate or visual inspection) should be performed promptly 41.
Smoking history (pack‑years) is essential for assessing lung‑cancer risk 41.
Chronic productive cough suggests bronchiectasis 41.
Constitutional symptoms (weight loss, night sweats, fever) raise suspicion for tuberculosis or malignancy 41.
Recent travel to endemic areas or known exposure to tuberculosis should be queried 41, 42.
Cardiovascular disease and thromboembolic risk factors are relevant comorbidities 41, 42.
Skin findings such as telangiectasias may indicate hereditary hemorrhagic telangiectasia 41.

Diagnostic Workup

CT chest with intravenous contrast is the preferred first‑line imaging for stable patients, providing ≈77 % diagnostic accuracy versus ≈26 % for chest radiograph alone 41, 42.
In unstable patients with massive hemoptysis, bronchial artery embolization (BAE) should be performed immediately without preceding CT or bronchoscopy, as delays significantly increase mortality 41, 42.
Bronchoscopy in unstable massive hemoptysis is indicated solely for airway clearance and tamponade, not for diagnosis 41.
In stable mild‑to‑moderate hemoptysis, bronchoscopy is used to localize the bleeding site when CT is nondiagnostic 41.

Management Strategies

Massive (Unstable) Hemoptysis

Immediate bronchial artery embolization achieves hemostasis in 73–99 % of cases 41, 42.
Delaying BAE for diagnostic procedures (CT or bronchoscopy) markedly raises mortality risk 41, 42.

Non‑Massive (Mild‑to‑Moderate) Hemoptysis

When conservative medical therapy fails, BAE provides immediate bleeding cessation in 93 % of patients 42.
For malignancy‑related bleeding, BAE is generally palliative and may be used as a bridge to definitive therapy 42.
In aspergilloma‑related massive hemoptysis, BAE followed by definitive surgical resection is recommended; BAE alone carries a 55 % recurrence rate 42.

Recurrence & Follow‑Up

Overall recurrence after BAE ranges from 10 % to 55 % 42.
Highest recurrence rates are observed in:
- Chronic pulmonary aspergillomas (55 %) 42;
- Malignancy 42;
- Sarcoidosis 42.
Recurrence mechanisms:
- ≤ 3 months: incomplete or missed embolization of bleeding arteries 42;
- > 3 months: development of vascular collaterals or recanalization 42.
Prior to repeat BAE, CT angiography (or contrast‑enhanced CT) should be performed for arterial mapping 42.
Repeat BAE does not increase morbidity or mortality 42.
Patients should receive close outpatient follow‑up because of the 10–55 % recurrence risk 42.

Prognostic Indicator

The rate of bleeding (speed of blood loss) predicts mortality more reliably than the absolute volume of blood expectorated 41, 42.

Acute Management of Massive Hemoptysis in Unstable Adults

Immediate Assessment and Resuscitation

In patients with massive hemoptysis (≥240 mL/24 h or any volume causing hypoxia, respiratory distress, or hemodynamic instability), secure the airway with a single‑lumen cuffed endotracheal tube, obtain large‑bore intravenous access, deliver high‑flow oxygen, and proceed directly to bronchial artery embolization (BAE) without prior bronchoscopy or CT; delays for bronchoscopy or imaging markedly increase mortality. 43
Rapid bleeding rate is a more accurate predictor of mortality than total volume; any rapid bleeding associated with hypoxia should be classified as massive hemoptysis. 43
Unstable patients frequently present with tachypnea and tachycardia; these signs are more common than visible cyanosis in hypoxemic individuals. 44
Signs of respiratory distress—including use of accessory muscles, inability to speak full sentences, and altered mental status—should prompt immediate airway protection and hemodynamic support. [43][44]
Obtain an arterial blood gas in all critically ill patients and in any patient with SpO₂ < 94 % on room air or supplemental oxygen to guide ventilation and perfusion management. 43

Oxygen and Hemodynamic Support

Initiate high‑flow oxygen via a reservoir mask at 15 L/min when SpO₂ < 85 %; thereafter titrate to maintain SpO₂ 94–98 % to optimize tissue oxygenation while avoiding hyperoxia. [43][44]

Diagnostic Considerations for Unstable Patients

In the unstable setting, bronchial artery embolization should be performed without preceding CT angiography, as the time saved improves hemostasis rates (73–99 % immediate control). [43][44]

Management of Mild‑to‑Moderate Hemoptysis (5–240 mL/24 h)

For patients with mild‑to‑moderate hemoptysis, deliver supplemental oxygen using nasal cannula (2–6 L/min) or simple face mask (5–10 L/min) to achieve SpO₂ 94–98 %; if target saturation cannot be reached, upgrade to a reservoir mask at 15 L/min. [43][44]
Continue airway clearance therapies (e.g., chest physiotherapy, suction) in patients with scant or mild‑to‑moderate hemoptysis, as discontinuation is not indicated. 45
Maintain aerosolized bronchodilator and inhaled antibiotic therapies in these patients, but discontinue aerosolized hypertonic saline during massive hemoptysis because it may exacerbate bleeding. 45

Differential Diagnosis in Adults with Hemoptysis

Pulmonary embolism should be considered in patients with hemoptysis who have thromboembolic risk factors; appropriate imaging is warranted when clinical suspicion is high. 44